Pharmacogenomics and Clopidogrel
Author:
- Steven E. NissenSNSteven E. Nissen
- 28 December 2011
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 306 (24) , 2727-2728
Abstract
On March 12, 2010, the US Food and Drug Administration (FDA) announced that clopidogrel would receive a “boxed warning,” the agency's highest level of alert (BoKeywords
This publication has 5 references indexed in Scilit:
- Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysisBMJ, 2011
- Recent progress and clinical importance on pharmacogenetics in cancer therapyClinical Chemistry and Laboratory Medicine (CCLM), 2011
- Faculty Opinions recommendation of Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.2010
- Effects ofCYP2C19Genotype on Outcomes of Clopidogrel TreatmentNew England Journal of Medicine, 2010
- Do Pressures to Publish Increase Scientists' Bias? An Empirical Support from US States DataPLOS ONE, 2010